State of the Art and New Trends from the 2022 Gism Annual Meeting-Reference-Cited by-同舟云学术

State of the Art and New Trends from the 2022 Gism Annual Meeting

Published:2023-05-17 Issue:10 Volume:24 Page:8902
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Ferrero Ivana¹,Proto Camilla Francesca²^ORCID,Banche Niclot Alessia Giovanna Santa²,Marini Elena²^ORCID,Pascucci Luisa³^ORCID,Piccinini Filippo⁴⁵^ORCID,Mareschi Katia¹²^ORCID

Affiliation:

1. Stem Cell Transplantation and Cellular Therapy Laboratory, Paediatric Onco-Haematology Division, Regina Margherita Childrens’ Hospital, City of Health and Science of Turin, 10126 Turin, Italy

2. Department of Public Health and Paediatrics, University of Turin, 10126 Turin, Italy

3. Department of Veterinary Medicine, University of Perugia, 06125 Perugia, Italy

4. IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy

5. Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40136 Bologna, Italy

Abstract

The 2022 Italian Mesenchymal Stem Cell Group (Gruppo Italiano Staminali Mesenchimali, GISM) Annual Meeting took place on 20–21 October 2022 in Turin (Italy), with the support of the University of Turin and the City of Health and Science of Turin. The novelty of this year’s meeting was its articulation, reflecting the new structure of GISM based on six sections: (1) Bringing advanced therapies to the clinic: trends and strategies, (2) GISM Next Generation, (3) New technologies for 3D culture systems, (4) Therapeutic applications of MSC-EVs in veterinary and human medicine, (5) Advancing MSC therapies in veterinary medicine: present challenges and future perspectives, (6) MSCs: a double-edged sword: friend or foe in oncology. National and international speakers presented their scientific works with the aim of promoting an interactive discussion and training for all attendees. The atmosphere was interactive, where ideas and questions between younger researchers and senior mentors were shared in all moments of the congress.

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

https://www.mdpi.com/1422-0067/24/10/8902/pdf

Reference16 articles.

1. Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union;Pellegrini;Stem Cells Transl. Med.,2018

2. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium;Pellegrini;Lancet,1997

3. The European Parliament, and The Council of the European Union (2007). Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance). Off. J. Eur. Union, 324, 121–137.

4. (2015). Holoclar (Standard No. EMA/6865/2015 EMEA/H/C/002450).

5. Regenerating Eye Tissues to Preserve and Restore Vision;Stern;Cell Stem Cell,2018